estimates of 1:2 500 to 1:5 000, its true prevalence is unknown, as some affected individuals may remain asymptomatic and others may be misdiagnosed. The importance of this unusual heart muscle disease is in its role as a major cause of sudden cardiac death in the young, especially athletes. (1, 2, 3, 19) PATHOGENESIS ARVC is familial in up to 50% of cases, with an autosomal dominant pattern of inheritance occurring in the majority. Rarer recessive modes of inheritance, however, do occur. One of these may be associated with abnormalities of skin (palmoplantar hyperkeratosis) and hair (wooly hair): the so-called Naxos disease. (4, 6, 19) The causative genes encode proteins of cell junctions (plakoglobin, plakophilin, desmoglein, desmocollin, desmoplakin), which mediate cellcell interaction, allowing for both mechanical and electrical coupling of adjacent cells. Mechanical coupling is important for providing structural integrity and allowing synchronous contraction of myocardium, while electrical coupling, via gap junctions, allows for rapid spread of depolarizing electrical waves. (4, 6, 19) Mutations may lead to remodeling of the intercalated disks of cell junctions, resulting in loss of the structural integrity of the myocardium and myocyte death, with replacement by fi brosis and adipocytes. This dystrophy of the right ventricular myocardium with fi bro-fatty replacement, which is the pathological hallmark of ARVC, serves as substrate for the development of life-threatening arrhythmias ( Figure 1 ). (4, 6, 19) Since heritable penetrance of ARVC is incomplete and genetic mutations within families have been shown to display variable phenotypic expression, both environmental factors and other genetic modifi ers have been implicated in its pathogenesis. Endurance sport and intense or prolonged physical activity have been consistently shown, in both humans and animal models of ARVC, to be a major modifi er in terms of frequency and severity of symptoms, as well an increased risk of death. Endurance sport in ARVC is associated with a 5-fold increase in the risk of sudden death in the young.
CLINICAL
The clinical picture is often described in four ''classical'' phases: (5) 1. The concealed phase, with either subtle or no structural changes, occurs in affected individuals, who despite being asymptomatic, remain at risk of sudden cardiac death (SCD) from an arrhythmia during episodes of extreme exertion. These individuals may be identifi ed through family screening; however, in a signifi cant proportion the diagnosis is fi rst established at postmortem examination, the initial presentation having been SCD. 
DIAGNOSTIC EVALUATION
A clinical diagnosis is achieved by demonstrating functional and structural alterations of the right ventricle, coupled with depolarization and repolarization abnormalities, arrhythmias with LBBB morphology (Figure 2 ) and fi bro-fatty replacement on histology (Figure 1 ). ARVC is confi rmed by a combination of 2 major, 1 major and 2 minor, or 4 minor criteria (Table 1) . (4) The main differential diagnoses include idiopathic right ventricular outfl ow tract tachycardia, myocarditis, dilated cardiomyopathy and sarcoidosis. (4, 5, 19) An ECG is essential in the evaluation of ARVC, providing both diagnostic and prognostic information. Abnormalities on ECG are detected in up to 90% of ARVC cases. Features include the presence of diffuse precordial T-wave inversions (beyond V2), an Epsilon wave in V1, widened localized QRS complex in leads V1-V3 (parietal block) and prolonged S-wave upstroke (≥ 55 ms) in V1-V3 ( Figure 3 ). (8, 9, 19 T-wave inversion in leads V1-V3 in the absence of RBBB and coronary disease is a well-established electrocardiographic feature of ARVC and is a minor criterion (Table 1 ). An epsilon wave (defi ned as a discrete wave following the QRS complex in V1-V3) and parietal block are both major diagnostic criteria ( S-wave upstroke in V1-V3, the most prevalent electrocardiographic feature, is seen in 95% of the patients. It correlates with disease severity and the induction of ventricular tachycardia at EPS. (9, 19) EPS should be considered in all individuals where ARVC is suspected or confi rmed, as it has important diagnostic, prognostic and therapeutic utility. Inducibility of VT during EPS, correlates with prognosis, identifying individuals for ICD and/or radiofrequency ablation. (4, 14, 15, 19) Electroanatomic voltage mapping is able to detect areas of low voltage corresponding to myocardial atrophy with fi bro-fatty replacement, enabling distinction between ARVC and idiopathic right ventricular outfl ow tract tachycardia. As the disease process is patchy, this mapping also allows for more directed targeting of endomyocardial biopsy. (18, 19) RV angiography (RVA) is the imaging gold standard in ARVC and may demonstrate the classical features of localized aneurysms, prominent trabeculations of the RV and global dilation with decreased ejection fraction ( Figure 4 ). (19, 21) Echocardiography, despite being widely available and frequently performed, has a low sensitivity for the detection of ARVC due to the diffi culty of imaging the RV. Despite these shortcomings, it remains useful as the fi rst-line non-invasive imaging modality in assessing both presence of disease at primary evaluation in suspected ARVC and in family screening and also, by means of serial examinations, progression during the follow-up of affected patients. Both functional and structural abnormalities can be evaluated, the detection of which may avoid the need for invasive RVA or costly cardiac magnetic resonance imaging (CMRI). (10, 19) CMRI has become integral to the evaluation of ARVC because it is noninvasive, with increased sensitivity over echocardiography. Accurate B: A sensitive measurement in ARVC that may be positive even before Epsilon waves can be discerned, is the duration of the S wave upstroke >55ms. In this patient, the measurement from the nadir of the S wave to termination of the QRS or when the S wave upstroke reaches baseline is 70ms, which is abnormal. 
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Diagnostic Clues
Family History
Unexplained sudden death in young or middle aged family member(s)
ECG fi ndings
T-wave inversions beyond lead V1
Epsilon waves in leads V1-V3 has been shown that the sensitivity and specifi city of CMRI are directly related to the experience of the radiologist in the reading of ARVC cases. (11, 12, 19) Multidetector Cardiac CT has shown promise as an alternative imaging modality with the added benefi t of coronary anatomy evaluation. (13) TREATMENT Treatment of ARVC is directed toward preventing life-threatening ventricular arrhythmias. This is achieved by sports avoidance and a combination of anti-arrhythmic drugs, radiofrequency ablation and ICDs. (5, 14, 15, 19) All forms of intense physical activity and endurance sport should be prohibited; competitive sport is also to be avoided. These activities are associated with an unacceptably high risk of death and avoidance has been shown to be associated with a reduction in SCD among
participants. An exercise test may be of benefi t in identifying individuals at risk for developing exercise-induced arrhythmias but, as it is unable to mimic the competitive sport situation with its probable associated catecholamine rise and sympathetic effects, its sensitivity is low. (16, 22) Beta-blockers are the most commonly used drugs. Alternative agents include sotalol and amiodarone.
Radiofrequency ablation (RFA) may be used as the sole treatment modality in selected cases where the VT originates from a focal area amenable to ablation; however, it is mostly combined with antiarrhythmic agents or an ICD. It is indicated particularly for drug failure and break-through arrhythmias or frequent ICD shock therapy.
Although effective in the short term, RFA is not curative and is associated with a high recurrence of VT of 40% at 3 years, probably due to the progressive nature of the disease. (14) Major risk factors for adverse prognosis are: young age, family history of juvenile sudden death, QRS dispersion ≥ 40 ms, T-wave inversion, left ventricular involvement, cardiac failure, ventricular tachycardia, syncope and previous cardiac arrest. Sports avoidance, ICDs and heart transplant (in severe heart failure) are life-saving interventions. (14, 15, 16, 19 
SA ARVC REGISTRY
International registries have been established in order to address issues relating to pathogenesis, prognosis and treatment. Much of our understanding of ARVC emanates from this. (5, 6, 7, 9, 11, 12, 14, 19, 20) To this end, The functional organization of the registry has been formalized (see the organogram in Figure 6 ). The registry has six major missions: DNA/ Tissue bank, epidemiology, risk assessment and evaluation of therapy, imaging, pathological diagnosis and diagnostic validation.
DNA / Tissue banking
Blood samples for DNA analysis are obtained from all confi rmed cases and family members to determine gene loci and to identify specifi c abnormal genes. The LV size is preserved.
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This will enable genotype-phenotype correlation and facilitate family screening for identifi ed mutations.
Epidemiology
The screening for and the detection of familial occurrence by means of ECG, SAECG, Holter 24-hour ECG recording, exercise stress test, echocardiography, CMRI and genetic screening of known mutations will expand the limited epidemiological database of this condition in southern Africa. The pathology reports of explanted hearts obtained at cardiac transplantation, will be reviewed for features consistent with ARVC. Anatomical and forensic pathologists across South Africa will be encouraged to forward identifi ed potential cases for review.
Risk stratifi cation and evaluation of therapies
The main aim is to identify prognostic factors and evaluate long-term effi cacy of current pharmacological and non-drug therapy.
Imaging
In addition to evaluating the diagnostic and prognostic value of existing imaging modalities and techniques, new MRI protocols, such as those utilizing cine Displacement Encoding with Stimulated Echoes (cine DENSE) for quantifying regional myocardial strain based on phase contrast images optimized for RV, are being developed using the registry patients to enhance earlier disease detection.
Pathology registry and tissue bank
A cardiac pathology registry has been set up to collect either heart specimens or endomyocardial biopsies. Protocols have been developed for processing and analysis of these specimens including immunohistochemistry, histochemistry, electron microscopy and myocyte culture. Insight will be gained into the etiopathogenesis of the disease and the diagnostic value of endomyocardial biopsy in the workup of suspected cases of ARVC. A novel genetic mutation in the plakophyllin gene was discovered in one family that presented with early progressive disease proceeding to cardiac transplantation in 2 siblings.
RESULTS AND REGISTRY DATA
DISCUSSION
This registry represents the largest cohort of ARVC patients from the African continent. The results confi rm the clustering of ARVC in families, the signifi cant role of endurance sport and the high mortality of ARVC. (4, 6, 16, 19) Despite the short existence of the registry and minimal fi nancial support, considerable strides have been made with respect to recruitment, data collection and novel fi ndings. In this regard it compares favourably with the output of other international registries. (20) There remains a call for cardiologists and physicians across South Africa to be vigilant in identifying affected individuals and to be diligent in referring all suspected or confi rmed cases of ARVC to the registry in order for it to achieve its goals.
Contact details for referral of confi rmed and suspected cases of ARVC:
arvc.sa@uct.ac.za
